Can infliximab serve as a new therapy for neuropsychiatric symptoms?-Reference-Cited by-同舟云学术

Can infliximab serve as a new therapy for neuropsychiatric symptoms?

Published:2024-09-03 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Rahmati-Dehkordi Fatemeh,Birang Nafiseh,Jalalian Mohammad Naser,Tamtaji Zeinab,Dadgostar Ehsan,Aschner Michael,Shafiee Ardestani Mehdi,Jafarpour Hamed,Mirzaei Hamed,Nabavizadeh Fatemeh,Tamtaji Omid Reza

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00210-024-03397-w.pdf

Reference120 articles.

1. Araújo EP, De SouzaUeno CM, Cintra DE, Bertolo MB, Carvalheira JB, Velloso LA (2007) Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinol 148(12):5991–5997

2. Armstrong A, McBride S, Spelman L, Fernández-Peñas P, Rich P, Martin G, Hellot S (2022) 33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 87(3):AB175

3. Bakker A, Mathijssen H, Azzahhafi J, Swaans M, Veltkamp M, Keijsers R, Grutters J (2021) Effectiveness and safety of infliximab in cardiac sarcoidosis. Int J Cardiol 330:179–185

4. Balzano T, Dadsetan S, Forteza J, Cabrera-Pastor A, Taoro-Gonzalez L, Malaguarnera M, Felipo V (2020) Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversed by anti-TNF-α treatment. J Hepatol 73(3):582–592. https://doi.org/10.1016/j.jhep.2019.01.008

5. Bekhbat M, Chu K, Le NA, Woolwine BJ, Haroon E, Miller AH, Felger JC (2018) Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology 98:222–229. https://doi.org/10.1016/j.psyneuen.2018.09.004